RyR2 QQ2958 Genotype and Risk of Malignant Ventricular Arrhythmias

Cardiology Research and Practice
Francesca GalatiSerafina Massari

Abstract

Ventricular arrhythmias are one of the most common causes of death in developed countries. The use of implantable cardiac defibrillators is the most effective treatment to prevent sudden cardiac death. To date, the ejection fraction is the only approved clinical variable used to determine suitability for defibrillator placement in subjects with heart failure. The purpose of this study was to assess whether genetic polymorphisms found in the ryanodine receptor type 2 (Q2958R) and histidine-rich calcium-binding protein (S96A) might serve as markers for arrhythmias. Genotyping was performed in 235 patients treated with defibrillator for primary and secondary prevention of arrhythmias. No significant association was found between the S96A polymorphism and arrhythmia onset, whereas the QQ2958 genotype in the ryanodine receptor gene was correlated with an increased risk of life-threatening arrhythmias. Concurrent stressor conditions, such as hypertension, seem to increase this effect. Our findings might help to better identify patients who could benefit from defibrillator implantation.

References

Jan 17, 2002·The New England Journal of Medicine·H V HuikuriR J Myerburg
Dec 14, 2002·Biochemical and Biophysical Research Communications·Eunyoung KimWoo Jin Park
Jun 14, 2005·Pharmacology & Therapeutics·Masafumi YanoMasunori Matsuzaki
Apr 8, 2006·Journal of Molecular and Cellular Cardiology·Kimberly N GregoryEvangelia G Kranias
Jul 26, 2006·Circulation·Steven PoelzingIsabelle Deschênes
May 29, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Demetrios A ArvanitisEvangelia G Kranias
Feb 16, 2012·Circulation. Arrhythmia and Electrophysiology·Rasmus Havmöller, Sumeet S Chugh
Jul 31, 2012·PloS One·Annukka M LahtinenVeikko Salomaa

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
genotyping

Software Mentioned

MedCalc

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Current Treatment Options in Cardiovascular Medicine
Jaydutt B Patel, Bruce A Koplan
The New England Journal of Medicine
Arthur J MossMulticenter Automatic Defibrillator Implantation Trial II Investigators
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
Marcello Disertori, Nabil El-Sherif
© 2022 Meta ULC. All rights reserved